Patrick O Richard1,2, Michael A S Jewett1, Simon Tanguay3, Olli Saarela4, Zhihui Amy Liu4, Frédéric Pouliot5, Anil Kapoor6, Ricardo Rendon7, Antonio Finelli1. 1. Departments of Surgery and Surgical Oncology, Princess Margaret Cancer Centre, University Health Network and the University of Toronto, Toronto, ON, Canada. 2. Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada. 3. Department of Surgery, Division of Urology, McGill University Health Center, McGill University, Montreal, NS, Canada. 4. Dalla Lana School of Public Health, University of Toronto, NS, Canada. 5. Université Laval, Centre de Recherche du Centre Hospitalier Universitaire de Québec, Québec, NS, Canada. 6. Department of Surgery, Division of Urology, McMaster University, Hamilton, NS, Canada. 7. QEII Health Sciences Centre, Department of Urology, Dalhousie University, Halifax, NS, Canada.
Abstract
OBJECTIVE: To validate, in a multi-institution review, the safety, accuracy and reliability of renal tumour biopsy (RTB) and its role in decreasing unnecessary treatment. MATERIALS AND METHODS: We conducted a multi-institution retrospective study of patients who underwent RTB to characterize a small renal mass (SRM) between 2011 and May 2015. Patients were identified using the prospectively maintained Canadian Kidney Cancer information system. Diagnostic and concordance rates were presented using proportions, whereas factors associated with a diagnostic RTB were identified using a logistic regression model. RESULTS: Of the 373 biopsied SRMs, the initial biopsy was diagnostic in 87% of cases. Of the 47 non-diagnostic biopsies, 15 had a repeat biopsy of which, 80% were diagnostic. When both were combined, therefore, a diagnosis was obtained in 91% of SRMs. Of these, 18% were benign. Size was the only factor found to be associated with achieving a diagnostic biopsy. RTB histology and nuclear grade (high or low) were found to be highly concordant with surgical pathology (86 and 81%, respectively). Of the discordant tumours (n = 16), all were upgraded from low to high grade on surgical pathology. Adverse events were rare (<1% of cases). CONCLUSION: The present multi-institution study confirms that RTB of SRMs is safe, accurate and reliable across institutions, while decreasing unnecessary treatment. Given our findings, RTBs may be a helpful tool with which to triage SRMs and guide appropriate management.
OBJECTIVE: To validate, in a multi-institution review, the safety, accuracy and reliability of renal tumour biopsy (RTB) and its role in decreasing unnecessary treatment. MATERIALS AND METHODS: We conducted a multi-institution retrospective study of patients who underwent RTB to characterize a small renal mass (SRM) between 2011 and May 2015. Patients were identified using the prospectively maintained Canadian Kidney Cancer information system. Diagnostic and concordance rates were presented using proportions, whereas factors associated with a diagnostic RTB were identified using a logistic regression model. RESULTS: Of the 373 biopsied SRMs, the initial biopsy was diagnostic in 87% of cases. Of the 47 non-diagnostic biopsies, 15 had a repeat biopsy of which, 80% were diagnostic. When both were combined, therefore, a diagnosis was obtained in 91% of SRMs. Of these, 18% were benign. Size was the only factor found to be associated with achieving a diagnostic biopsy. RTB histology and nuclear grade (high or low) were found to be highly concordant with surgical pathology (86 and 81%, respectively). Of the discordant tumours (n = 16), all were upgraded from low to high grade on surgical pathology. Adverse events were rare (<1% of cases). CONCLUSION: The present multi-institution study confirms that RTB of SRMs is safe, accurate and reliable across institutions, while decreasing unnecessary treatment. Given our findings, RTBs may be a helpful tool with which to triage SRMs and guide appropriate management.
Authors: Patrick O Richard; Lisa Martin; Luke T Lavallée; Philippe D Violette; Maria Komisarenko; Andrew J Evans; Kunal Jain; Michael A S Jewett; Antonio Finelli Journal: Can Urol Assoc J Date: 2018-04-06 Impact factor: 1.862
Authors: Scott P Campbell; Antonios Tzortzakakis; Mehrbod S Javadi; Mattias Karlsson; Lilja B Solnes; Rimma Axelsson; Mohamad E Allaf; Michael A Gorin; Steven P Rowe Journal: Br J Radiol Date: 2018-02-27 Impact factor: 3.039
Authors: Charlie J Gillis; Ricardo Rendon; Landan P MacDonald; Michael A S Jewett; Christopher French; Henry Ajzenberg; Ashraf Almatar; Mohammed Abdolell; Michael Organ Journal: Can Urol Assoc J Date: 2019-11-29 Impact factor: 1.862
Authors: Ahmet Bindayi; Michelle L Mcdonald; Alp T Beksac; Gerant Rivera-Sanfeliz; Ahmed Shabaik; Fiona Hughes; Lejla Aganovic; Donna E Hansel; Ithaar H Derweesh Journal: Turk J Urol Date: 2018-07
Authors: Roy Mano; Cihan Duzgol; Maz Ganat; Debra A Goldman; Kyle A Blum; Andrew W Silagy; Aleksandra Walasek; Alejandro Sanchez; Renzo G DiNatale; Julian Marcon; Mahyar Kashan; Maria F Becerra; Nicole E Benfante; Jonathan A Coleman; Michael W Kattan; Paul Russo; Oguz Akin; Irina Ostrovnaya; A Ari Hakimi Journal: Urol Oncol Date: 2021-09-25 Impact factor: 3.498